FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318417271> ?p ?o ?g. }

• W2318417271 endingPage "A674" @default.
• W2318417271 startingPage "A674.1" @default.
• W2318417271 abstract "<h3>Objectives</h3> Safety, efficacy, & radiographic progression in GLM-treated pts from long-term extension of GO-REVEAL is presented. <h3>Methods</h3> 405 PsA pts (≥3 SJ, ≥3 TJ counts) were rand to SC PBO (Grp1, n=113), GLM50mg (Grp2, n=146), or GLM100mg (Grp3, n=146) q4wks thru wk20. Concomitant MTX at baseline (BL) was allowed but not required. At wk16, pts with <10% improvement in SJ&TJ were eligible for rescue tx. All pts received GLM from wk24 forward. After wk52, pts could change GLM dose based on investigator judgment. The last GLM inj was at wk252; efficacy was assessed at wk256 based on rand grp&completer analyses using ACR response criteria, DAS28-CRP, PASI, HAQ, enthesitis/dactylitis assessments, NAPSI scores, & PsA-modified Sharp/van der Heijde Score (SHS). Safety evaluations included all pts who received at least one GLM dose thru 5yrs. <h3>Results</h3> Of 405 pts rand, 335 cont’d in the study at wk104, & 279 pts (69%) cont’d GLM thru wk252. 29% of Grp2 pts dose escalated to GLM100mg; 25% of Grp3 pts decreased dose from 100mg to 50mg. BL characteristics of pts who cont’d in the study at wk104 & efficacy at wk256 are provided(Table). ACR&PASI responses were similar in pts tx with or without MTX; changes from BL in SHS scores were minimal&numerically less in pts tx with GLM & MTXvs GLM alone. 88%, & 21% GLM-tx pts experienced AE & SAE, resp. 12% of pts d/c GLM due to AE, & 5% & 4% pts experienced malignancy (incl NMSC),& serious infection, resp. Antibodies to GLM were detected in 6% of pts. <h3>Conclusions</h3> Pt attrition thru 5yrs of GLM tx was low. GLM tx resulted in long-term maintenance of clinically meaningful responses in arthritic & skin components of PsA, improved physical function, & arrest of radiographic progression. No apparent differences between long-term safety&efficacy of 2 GLM doses administered q4wks were observed, however, interpretation of the data is limited due to tx changes allowed across rand grps. <h3>Disclosure of Interest</h3> A. Kavanaugh Grant/research support from: Janssen Research and Development, LLC, D. van der Heijde Grant/research support from: Janssen Research and Development, LLC, I. McInnes Grant/research support from: Janssen Research and Development, LLC, P. Mease Grant/research support from: Janssen Research and Development, LLC, G. G. Krueger Grant/research support from: Janssen Research and Development, LLC, D. Gladman Grant/research support from: Janssen Research and Development, LLC, Y. Zhou Employee of: Janssen Research and Development, LLC, J. D. Lu Employee of: Janssen Research and Development, LLC, Z. Xu Employee of: Janssen Research and Development, LLC, L. Noonan Employee of: Janssen Research and Development, LLC, A. Beutler Employee of: Janssen Research and Development, LLC" @default.
• W2318417271 created "2016-06-24" @default.
• W2318417271 creator A5004060946 @default.
• W2318417271 creator A5006796373 @default.
• W2318417271 creator A5020311509 @default.
• W2318417271 creator A5022397572 @default.
• W2318417271 creator A5025049914 @default.
• W2318417271 creator A5058110978 @default.
• W2318417271 creator A5063001450 @default.
• W2318417271 creator A5070461768 @default.
• W2318417271 creator A5071482630 @default.
• W2318417271 creator A5078634383 @default.
• W2318417271 creator A5087951148 @default.
• W2318417271 date "2013-06-01" @default.
• W2318417271 modified "2023-09-27" @default.
• W2318417271 title "SAT0270 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Long-Term Extension Results of the Randomized, Placebo-Controlled Study Go-Reveal" @default.
• W2318417271 doi "https://doi.org/10.1136/annrheumdis-2013-eular.1995" @default.
• W2318417271 hasPublicationYear "2013" @default.
• W2318417271 type Work @default.
• W2318417271 sameAs 2318417271 @default.
• W2318417271 citedByCount "1" @default.
• W2318417271 countsByYear W23184172712013 @default.
• W2318417271 crossrefType "journal-article" @default.
• W2318417271 hasAuthorship W2318417271A5004060946 @default.
• W2318417271 hasAuthorship W2318417271A5006796373 @default.
• W2318417271 hasAuthorship W2318417271A5020311509 @default.
• W2318417271 hasAuthorship W2318417271A5022397572 @default.
• W2318417271 hasAuthorship W2318417271A5025049914 @default.
• W2318417271 hasAuthorship W2318417271A5058110978 @default.
• W2318417271 hasAuthorship W2318417271A5063001450 @default.
• W2318417271 hasAuthorship W2318417271A5070461768 @default.
• W2318417271 hasAuthorship W2318417271A5071482630 @default.
• W2318417271 hasAuthorship W2318417271A5078634383 @default.
• W2318417271 hasAuthorship W2318417271A5087951148 @default.
• W2318417271 hasConcept C126322002 @default.
• W2318417271 hasConcept C141071460 @default.
• W2318417271 hasConcept C142724271 @default.
• W2318417271 hasConcept C204787440 @default.
• W2318417271 hasConcept C27081682 @default.
• W2318417271 hasConcept C2776260265 @default.
• W2318417271 hasConcept C2777575956 @default.
• W2318417271 hasConcept C2780132546 @default.
• W2318417271 hasConcept C2781290027 @default.
• W2318417271 hasConcept C71924100 @default.
• W2318417271 hasConceptScore W2318417271C126322002 @default.
• W2318417271 hasConceptScore W2318417271C141071460 @default.
• W2318417271 hasConceptScore W2318417271C142724271 @default.
• W2318417271 hasConceptScore W2318417271C204787440 @default.
• W2318417271 hasConceptScore W2318417271C27081682 @default.
• W2318417271 hasConceptScore W2318417271C2776260265 @default.
• W2318417271 hasConceptScore W2318417271C2777575956 @default.
• W2318417271 hasConceptScore W2318417271C2780132546 @default.
• W2318417271 hasConceptScore W2318417271C2781290027 @default.
• W2318417271 hasConceptScore W2318417271C71924100 @default.
• W2318417271 hasIssue "Suppl 3" @default.
• W2318417271 hasLocation W23184172711 @default.
• W2318417271 hasOpenAccess W2318417271 @default.
• W2318417271 hasPrimaryLocation W23184172711 @default.
• W2318417271 hasRelatedWork W1984864659 @default.
• W2318417271 hasRelatedWork W2000914229 @default.
• W2318417271 hasRelatedWork W2075378263 @default.
• W2318417271 hasRelatedWork W2109911339 @default.
• W2318417271 hasRelatedWork W2121667395 @default.
• W2318417271 hasRelatedWork W2158058290 @default.
• W2318417271 hasRelatedWork W2328099609 @default.
• W2318417271 hasRelatedWork W2914820538 @default.
• W2318417271 hasRelatedWork W2939011993 @default.
• W2318417271 hasRelatedWork W3087454845 @default.
• W2318417271 hasVolume "72" @default.
• W2318417271 isParatext "false" @default.
• W2318417271 isRetracted "false" @default.
• W2318417271 magId "2318417271" @default.
• W2318417271 workType "article" @default.